Update: Moderate lifetime drinking may lead to lower Alzheimer-related beta amyloid deposits in the brain

By SharpBrains | April 24, 2020

__ Time for a new edi­tion of Sharp­Brains’ e‑newsletter. #1. First of all, it’s not all bad news this month. Study finds that mod­er­ate life­time drink­ing may lead to low­er Alzheimer-relat­ed beta amy­loid deposits in the brain #2. And, talk about per­son­al­ized med­i­cine! This fas­ci­nat­ing study show­ing how brain imag­ing (fMRI) + machine learn­ing + inten­sive, non-invasive…

Read More

Digital health start-ups raised a record $3.1 billion in Q1; focus will likely evolve from providers to consumers and employers

By SharpBrains | April 20, 2020

__ Dig­i­tal health firms raised record sums before Covid-19 hit (Med­C­i­ty News): “Dig­i­tal Health star­tups raised a record-break­ing $3.1 bil­lion in the first quar­ter of 2020, accord­ing to a report released Mon­day by Rock Health. But now faced with a glob­al pan­dem­ic, the trend is unlike­ly to continue

Read More

Meditation apps have gone mainstream in the covid-19 era

By SharpBrains | April 13, 2020

__ 1. Best med­i­ta­tion apps: prac­tice mind­ful­ness with Head­space, Calm and more (TechRadar): “The best med­i­ta­tion apps could help you to sleep bet­ter, reduce your stress lev­els and find some much-need­ed inner peace. But giv­en the sit­u­a­tion right now with Covid-19, even if med­i­ta­tion apps just give you a break from the news and a…

Read More

Verily and LivaNova accelerate efforts to detect and treat depression

By SharpBrains | March 2, 2020

__ Heads-up about a cou­ple fas­ci­nat­ing devel­op­ments over the last few weeks. 1) Verily’s Bold New Project Aims to Pre­dict Depres­sion Using Your Phone (Sin­gu­lar­i­ty­Hub): “Depres­sion is a shift­ing, amor­phous beast that silent­ly haunts mil­lions. It’s also dif­fi­cult to pin­point. Psy­chi­a­try has for­mu­lat­ed well-test­ed ques­tion­naires to diag­nose depres­sion. But these tests require patients to reach out…

Read More

Large study finds positive yet mixed results from Akili’s digital therapeutic for kids with ADHD

By SharpBrains | February 25, 2020

__ Full pub­li­ca­tion of piv­otal tri­al data out­lines Akil­i’s case for FDA reg­u­la­tion (Mobi­Health­News): “A full tran­script of STARS-ADHD — the piv­otal tri­al of Akili Interactive’s video game-like pedi­atric atten­tion deficit treat­ment — has been pub­lished in The Lancet Dig­i­tal Health jour­nal, pro­vid­ing onlook­ers a clear view of data fuel­ing the dig­i­tal ther­a­peu­tic company’s pending…

Read More

First Digital Health Formulary by Express Scripts includes CBT-based programs to treat depression, anxiety and insomnia

By SharpBrains | December 13, 2019

_____ Express Scripts Launch­es First Dig­i­tal Health For­mu­la­ry for Apps & Devices (HIT Con­sul­tant): “Start­ing in Jan­u­ary 2020, Express Scripts Dig­i­tal Health For­mu­la­ry will ini­tial­ly include 15 solu­tions for remote mon­i­tor­ing ser­vices and dig­i­tal ther­a­peu­tics that aid in the man­age­ment of eight of the country’s most com­mon chron­ic con­di­tions: dia­betes, pre­di­a­betes, hyper­ten­sion, asth­ma, pul­monary disease,…

Read More